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ABSTRACT
The bacterial transposon, Tn7, inserts into a single
site in the Escherichia coli chromosome termed
attTn7 via the sequence-specific DNA binding of
the target selector protein, TnsD. The target DNA
sequence required for Tn7 transposition is located
within the C-terminus of the glucosamine synthetase
(glmS) gene, which is an essential, highly conserved
gene found ubiquitously from bacteria to humans.
Here, we show that Tn7 can transpose in vitro adja-
cent to two potential targets in the human genome:
the gfpt-1 and gfpt-2 sequences, the human analogs
of glmS. The frequency of transposition adjacent
to the human gfpt-1 target is comparable with the
E.coli glmS target; the human gfpt-2 target shows
reduced transposition. The binding of TnsD to
these sequences mirrors the transposition activity.
In contrast to the human gfpt sequences, Tn7 does
not transpose adjacent to the gfa-1 sequence, the
glmS analog in Saccharomyces cerevisiae. We also
report that a nucleosome core particle assembled on
the human gfpt-1 sequence reduces Tn7 transposi-
tion by likely impairing the accessibility of target
DNA to the Tns proteins. We discuss the implications
of these findings for the potential use of Tn7 as asite-
specific DNA delivery agent for gene therapy.
INTRODUCTION
The bacterial transposon Tn7 is unique among transposons, in
that it is able to target a speciﬁc site in the Escherichia coli
genome called attTn7 (1). The Tn7 modus operandi is ingeni-
ous: the 35 bptarget recognitionsequenceisentirelycontained
within a highly conserved, essential gene, glucosamine syn-
thetase (glmS), with the actual site of insertion located 25 bp
downstreamofthecodingsequence(seeschematicinFigure1)
such that Tn7 insertions are non-deleterious to the host (1).
The reconstituted in vitro TnsABC+Dtranspositionreaction
has been fundamental to our understanding of the biochem-
istry of Tn7 transposition (2) and also provides a powerful
method to evaluate potential target sites for Tn7 transposi-
tion (3,4). Four Tn7 proteins are required for transposition
into attTn7: TnsD, the target selector, binds in a sequence-
speciﬁc manner to attTn7 and recruits TnsC, an ATP-
dependent, non-sequence speciﬁc DNA-binding, regulator
protein, followed by TnsA and TnsB, which together consti-
tute the transposase and carry out the chemistry of recomb-
ination (1,5). Transposition is stringently regulated such that
TnsD binding to the target DNA is the ﬁrst step in assembling
a nucleoprotein complex containing TnsABC+D, target DNA
and donor DNA; only then can the DNA breakage and joining
reactions be initiated (2,3,6).
What are the particular target DNA requirements for attract-
ing Tn7 transposition? The DNA sequence, from nucleotide
positions+23 to+58 (shown inFigure1),whichconstitutesthe
binding site for TnsD, the target selector protein, is sufﬁcient
for targeting Tn7 transposition (7). The DNA sequence else-
where, i.e. around the actual site of insertion (nucleotide
position 0) and all the way up to nucleotide position +22
(Figure 1), can be varied without signiﬁcantly affecting Tn7
transposition into the target site. The DNA sequence from +23
to +58, required for targeting Tn7 transposition, is contained
entirely within the C-terminus of the glmS gene (Figure 1).
Analogs of the glmS gene are found in all organisms
from bacteria and yeast to humans. There are two analogs of
glmS in the human genome, glutamine-fructose-6-phosphate-
transaminase-1 and 2 (gfpt-1 and gfpt-2) located at chromo-
some 2p13 and 5q34–q35 (8–10). In addition to the analogs of
glmS, a sequence search also reveals an identical copy of the
E.coli attTn7 target sequence located on chromosome 11
(clone RP11-159C12) of the human genome. The glmS analog
in Saccharomyces cerevisiae, located on chromosome XI, is
termed gfa-1 (11). Glucosamine synthetase, the product of the
glmS gene, is the ﬁrst and rate-limiting enzyme in hexosamine
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doi:10.1093/nar/gki227metabolism (12). The C-terminal portion of the GlmS protein,
which contains the isomerase domain, is very highly con-
served. Indeed, the amino acid sequence is identical for all
four proteins listed above; differences in nucleotide sequences
are limited primarily to the ‘wobble’ position in each case
(Figure 1). Thus, the highly conserved C-terminal region of
glmS analogs presents potential target sites for Tn7 transposi-
tion in the human genome, as well as that of yeast and other
organisms.
The high frequency and site-speciﬁcity of Tn7 transposition
make Tn7 an attractive candidate for developing a reliable,
site-speciﬁc DNA delivery system for eukaryotic genomes
withpotential usein gene therapy. Severalimportant questions
need to be addressed in this regard: Can TnsD, the target
selector protein, recognize and bind the human analogs of
glmS and will Tn7 transpose into this human attTn7-like
targets? If so, what is the relative frequency of Tn7
transposition? How would the Tns proteins interact with a
chromatinized target site?
Here, we show that Tn7cantranspose adjacent tothe human
gfpt-1 sequence in vitro at a frequency comparable with the
E.coli sequence; the human gfpt-2 sequence shows reduced
transposition. Transposition activityclosely mirrorsthe degree
of TnsD binding to glmS and the analogous gfpt-1 and gfpt-2
sequences. We alsoreport that the positioning of a nucleosome
on the human gfpt-1 sequence reduces Tn7 transposition by
likely blocking the accessibility of target DNA to the Tns
proteins. Interestingly, Tn7 does not transpose adjacent to
the gfa-1 sequence, the glmS analog in S.cerevisiae. We dis-
cuss theimplicationsoftheseobservationsforthepotentialuse
of Tn7 as a site-speciﬁc DNA delivery tool.
MATERIALS AND METHODS
Plasmids and DNA fragments: glmS analogs—the
human gfpt-1, gfpt-2 and yeast gfa-1 sequences
50 bp sequences around the putative Tn7 insertion site
(marked 0 on the sequences in Figure 1) of the human gfpt-1
and yeast gfa-1 genes were PCR-cloned into pCRII-TOPO
(Invitrogen) to yield target plasmids pPK222 and pPK221,
respectively. Similarly, the plasmid pPK230 was constructed
by cloning the analogous human gfpt-2 sequence into the
plasmid pLITMUS28. Plasmid pPK13 containing the E.coli
target sequence has been described previously (3). For the
in vitro transposition reactions, the Tn7-bearing Donor plas-
mid pPK21 contains 174 bp from the left end of Tn7 and 199
bp from the right end of Tn7 in a pUC19 vector. The chlor-
amphenicol resistance containing Tn7 donor pGPS2.1 and the
kanamycin resistance carrying Tn7 donor pEMD were used to
isolate and sequence Tn7 insertions into pPK222 and pPK230,
respectively (see below).
170 bp EcoRI-digested fragments from plasmids pPK222
and pPK211, the 180 bp SpeI–XbaI fragment from pPK230,
and the attTn7-containing 205 bp XbaI–HindIII fragment from
pPK13 (3) were all 30 end-labeled and puriﬁed using standard
protocol (13). These end-labeled target DNA fragments con-
taining glmS and its analogs were used for the in vitro experi-
ments detailed below.
Tn7 transposition reactions
Tn7 transposition reactions contained the following compon-
ents:  0.02 pmol 30 end-labeled target DNA, 0.05 pmol Tn7
donor containing plasmid pPK21, 0.5 pmol TnsD, 0.5 pmol
Figure 1. Comparison of glmS and its analogs bearing potential Tn7 target sites. The top portion is a schematic (not drawn to scale) of the Tn7 target site in E.coli
termedattTn7.Thecentralnucleotideofthe5bpduplicationuponTn7insertionisdenotednucleotideposition0,theTnsD-bindingsite(hatchedrectangle)ismarked
from +23 to +58, and the coding region of the glmS gene is marked by the thick arrow. The orientation-specificity of the Tn7 insertion with the right end located
proximaltotheglmSgeneandtheTnsD-bindingsiteisalsoshown.TheDNAsequencefrom+23to+58issufficientforTn7transpositioninvitroandinvivo.Below
thearrowarelistedtheconservedaminoacidsequenceforallfourgeneproducts.Thisisfollowedbythesequencecomparisonofthe30-terminalregionoftheE.coli
glmSgene,Homosapiensgfpt-1andgfpt-2genesandtheS.cerevisiaegfa-1gene.ThesequenceofthehumancloneRP11-159C12,whichisanexactcopyoftheE.coli
glmS target sequence, is also listed. Nucleotides in capitals are conserved and nucleotidesin lower case are divergentfrom the E.coli sequence. The sequence of the
5 bp duplication, which would result from Tn7 transposition, is also listed for each target sequence.
858 Nucleic Acids Research, 2005, Vol. 33, No. 3TnsC, 1.2 pmol TnsA and 0.3 pmol TnsB in a 24 ml reaction.
The reaction buffer included 24 mM HEPES, pH 7.6, 8 mM
Tris, pH 7.6, 1.7 mM ATP, 3.7 mM DTT, 0.2 mg/ml BSA,
15.4 mM magnesium acetate, 0.8 mg/ml sonicated salmon
sperm DNA, 73 mM KCl, 51 mM NaCl, 0.1 mM EDTA,
0.4 mM CHAPS and 4.7% glycerol. The reaction was staged
as follows: the target DNA, TnsC and TnsD were pre-
assembled in the reaction buffer by incubating at 30 C for
20 min; followed by the addition of the donor, TnsA, TnsB
and Mg
2+ and further incubation at 30 C for 30 min. The
reaction was stopped by phenol/chloroform extraction and
precipitation. The products of the transposition reaction
were run out on a 6% polyacrylamide gel, dried and subject
to phosphorimaging (Storm/Molecular Dynamics) to yield the
phosphorimage shown in Figure 2A. The bands on the gels
were quantiﬁed using ImageQuant (Molecular Dynamics) and
KaleidoGraph software (for Figure 2B).
The products of transposition include: the predominant sim-
ple insertion results from the excision of the Tn7 by double-
strand breaks at both ends of the transposon followed by
joining of both ends to the target, and a product termed SEJ,
where a single end of the transposon has undergone a double-
strand break followed by joining to the target. The product
marked with an asterisk in Figures 2A and 4 is not dependent
on the presence of the Tns proteins or transposition. These
bands were cut out of the gel, the DNA isolated and separated
on denaturing PAGE; they correspond in size to the unreacted
target DNA fragment (data not shown). The simplest explana-
tion for the observed altered mobility on native polyacrylam-
ide gels is that these are different conformers of the target
DNA fragment. Transposition reactions using the gfpt-2 target
sequence show a doublet for the simple insertion product. This
doubletmostlikelyresultsfrom the loss during electrophoresis
of the short DNA fragment on either side of the 5 bp gap
resulting from transposition. Tn7 Transposition into the larger
pPK230 plasmid containing the gfpt-2 target sequence results
in a single simple insertion product, which has been conﬁrmed
by sequencing (see below).
Sequencing of Tn7 insertions into human gfpt-1
and gfpt-2 sequences
Standard in vitro transposition reactions were carried out using
pPK222 and pPK221 as targets and pGPS2.1 (New England
Biolabs) as the Tn7 donor. For pPK230, the standard pEMD
donor was used. After transformation in E.coli and selection
for the appropriate antibiotic resistance, 20 independent col-
onies bearing Tn7-containing targets were picked, the plasmid
DNA isolated and sequenced. The 5 bp duplication resulting
from Tn7 transposition as well as the orientation of Tn7
insertion were mapped for each case.
Electrophoretic mobility shift assay (EMSA)
Various amounts of TnsD were incubated with radiolabeled
target DNA in standard binding reactions and run out on 5%
polyacrylamide gels as described elsewhere (3).
Reconstitution of nucleosome core particles on the
human gfpt-1 sequence
Nucleosome core particles were assembled on the 30 end-
labeled, 170 bp DNA fragment containing the human gfpt-1
sequence by the salt-gradient exchange method (14). Recon-
stitution was monitored on a 5% polyacrylamide gel as
described elsewhere (15). The gfpt-1 containing sequence
does not yield a completely reconstituted product; a mixture
comprised 85% nucleosome core particles and 15% free DNA.
When the conditions of reconstitution were altered, such as
decreased non-speciﬁc competitor DNA or increased histone
octamers, to improve the ratio of nucleosome core particles to
free DNA, we observed multimers and aggregates. Also, the
lackofuniquetranslationalpositioningofthe nucleosome core
particle on the DNA fragment and the large size of the Tn7
A
B
Figure2.Tn7transposesintothehumangfpt-1andgfpt-2sequencesbutnotthe
yeastgfa-1sequence.(A)Invitrotranspositionactivityofthevarioustargetsite
sequences. The image shows a native polyacrylamide gel used to separate the
products of the in vitro Tn7 transposition reaction. The reactions are divided
into four sets, each using one of the four, glmS, gfpt-1, gfpt-2 and gfa-1, target
sequences.Foreachset,thelanemarked0isacontrolwithoutanyTnsproteins;
lane 1 contained the TnsABC only reaction; and lanes 2–4 contained TnsABC
withincreasingamountsofTnsD(10–30ng).Thebandscorrespondingtotarget
DNA, simple insertion and single-end joining (SEJ) are marked. The bands
marked with an asterisk correspond to free target DNA that exhibit altered
mobilityundernativeconditionspotentiallydueto analternateDNA structure.
The gfpt-2 target shows a doublet for the simple insertion product due to an
altered DNA structure resulting from the loss during electrophoresis of a DNA
fragment located adjacent to the 5 bp gap resulting from transposition. For a
complete description of the various products, see Materials and Methods.
(B) Time course of Tn7 transposition into glmS and the human gfpt-1 and
gfpt-2 target sequences. A time course of Tn7 transposition into target DNA
bearing either the wild-type or human analogs of glmS was performed, the
productswereseparatedonpolyacrylamidegels[similartothegelin(A)],the%
simple insertion was quantified and plotted against time.
Nucleic Acids Research, 2005, Vol. 33, No. 3 859post-transposition complex prevented isolation of nucle-
osomal DNA after the Tn7 transposition reaction.
Transposition reactions with free and nucleosomal DNA
were identical to those described above, except that they
alsocontained the following components from the nucleosome
reconstitution reactions, i.e. 2 mM Tris, pH 7.6, 0.2 mM
EDTA and 21 mM NaCl in addition to the buffer conditions
in the reactions described earlier.
RESULTS
Tn7 transposes into the gfpt-1 and gfpt-2 human target
DNA sequences
End-labeled DNA fragments containing the human gfpt-1
and gfpt-2 sequences were used as targets for TnsABC+D-
mediated transposition reaction in vitro (3). Under limiting
conditions of the target selector protein, TnsD, the human
gfpt-1 sequence shows levels of transposition comparable
with that of the E.coli glmS sequence (compare the simple
insertion product, 32% with glmS and 31% with gfpt-1,i n
lanes 2 for each sequence in Figure 2A). The human gfpt-2
sequence also targets Tn7 transposition, but at a reduced level;
23% simple insertion with the gfpt-2 target as compared with
32% with the glmS target, shown in Figure 2A. Interestingly,
the analogous yeast gfa-1 sequence shows no Tn7 transposi-
tion (Figure 2A, right panel).
In order to better compare the ability of the E.coli and
human sequences to serve as targets for Tn7 transposition,
we analyzed the time course of recombination, the results
of which are graphed in Figure 2B. Tn7 transposition into
these targets, particularly at the earlier time points (2–
20 min), follows the following trend: glmS > gfpt-1 > gfpt-2
as seen in Figure 2B. We know from longer reactions (shown
in Figure 2A) that the glmS and human gfpt-1 sequence show
comparable levels of transposition, and the human gfpt-2
sequence shows reduced transposition.
We also performed standard in vitro Tn7 transposition
reactions using supercoiled target plasmids containing the
human gfpt-1 and gfpt-2, and the yeast gfa-1 sequences,
respectively, and mini-Tn7 containing donor plasmids. When
the products of the in vitro transposition reactions were trans-
formed and selected for targets containing Tn7 insertions (4),
the yeast target did not yield any colonies. Twenty independ-
ent Tn7 insertions into each of the two human sequence-
containing targets were selected and sequenced (4). As
expected, the 5 bp duplication, bearing the 50-AAGCA-30
sequence for the gfpt-1 sequence and the 50-CATCA-30
sequence for the gfpt-2 gene, was observed for each Tn7
insertion (Figure 1). Moreover, all the insertions were in
the appropriate orientation, i.e. the right end of Tn7 was
located proximal to the gfpt sequence as shown in Figure 1.
Thus, Tn7 insertions adjacent to the human gfpt-1 and gfpt-2
sequences in vitro are identical to those adjacent to the glmS
gene in E.coli in terms of site- and orientation-speciﬁcity.
The binding of TnsD to the human gfpt-1 target
is robust
Is the Tn7 transposition activity seen above due to different
binding afﬁnities of TnsD to the various target sequences?
We performed EMSAs (3) to determine the extent of TnsD
binding to the potential target sites. Not surprisingly, we found
that TnsD binding to the human gfpt-1 target was robust and
similar to the glmS target over a range of concentrations of
TnsD (Figure 3). Once again, quantiﬁcation of the binding
data revealed reduced binding of TnsD to the human gfpt-2
sequence as compared with the corresponding E.coli
sequence. In contrast, there was no detectable binding of
TnsD to the analogous yeast sequence (Figure 3) in agree-
ment with the lack of transposition activity seen in Figure 2A.
Thus, the levels of transposition observed for the various
target sequences closely mirror the extent of TnsD binding.
A nucleosome positioned on the human gfpt-1 sequence
reduces Tn7 transposition
We have shown above that the human gfpt-1 sequence is an
efﬁcient target for Tn7 transposition in vitro. However, DNA
in the eukaryotic cell is complexed with histones and other
proteins in the form of chromatin and the basic repeating unit
of the resulting structure is the nucleosome core particle (16).
The wrapping of DNA around the histone octamer produces
distinct structural perturbations in the target DNA that could
potentially enhance recombination, as observed for HIV
Integrase (17,18). Similarly, is a nucleosome core particle
assembled on the human gfpt-1 sequence a preferred target
for Tn7 transposition in vitro?
Using standard reconstitution methods (15), we assembled a
single nucleosome core particle on the 170 bp DNA fragment
from pPK222 containing the human gfpt-1 sequence to mimic
the putative target site for Tn7 transposition in human cells,
i.e. chromatinized DNA. It is important to note that unlike
‘model’ nucleosome positioning sequences, such as the 5S
rDNA from Xenopus borealis (16), this gfpt-1 containing se-
quence does not yield a uniquely positioned, completely re-
constituted product; a mixture comprising 85% nucleosome
Figure 3. TnsD, the target selector protein binds the human gfpt-1 and gfpt-2
sequences but not the yeast gfa-1 sequence. The EMSA shows the ability of
TnsD to bind to the various target sequences labeled glmS, gfpt-1, gfpt-2 and
gfa-1. For each sequence, increasing amounts of TnsD (0, 10, 20 and 30 ng)
wereaddedtothebindingreaction.BandscorrespondingtothetargetDNAand
the TnsD–target DNA complex are marked.
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terials and Methods) is obtained as shown in Figure 4, lane 1.
When transposition reactions were performed on free and
nucleosomal DNA, there was a marked decrease in Tn7 trans-
position into the nucleosomal target DNA (Figure 4, compare
the simpleinsertionproductinlanes 4and 5).Free DNA yields
 40% simple insertion, whereas nucleosomal DNA produces
 10% under similar conditions of transposition. Thus, nucle-
osomal DNA is not a preferred target for Tn7 transposition. A
simple explanation for the reduced transposition is that both
the TnsD-binding site and the insertion site are inaccessible to
the Tns proteins and that the large nucleoprotein complexes
required for the initiation of Tn7 transposition (3,6) cannot be
assembled on the nucleosomal DNA. The 10% simple inser-
tion seen in the case of nucleosomal DNA (Figure 4, lane 5)
probably results from Tn7 transposition into the free DNA
( 15%) present in the nucleosome assembly reaction as
seen in the EMSA in Figure 4, lane 2. Thus, the target
DNA sequence, when packaged into nucleosome core parti-
cles in vitro, can reduce Tn7 transposition.
DISCUSSION
TnsD binding and Tn7 transposition into targets
containing the eukaryotic analogs of glmS
Here, we have shown that the bacterial transposon Tn7 makes
insertions adjacent to the human gfpt-1 and gfpt-2 sequences,
but avoids the analogous gfa-1 sequence from S.cerevisiae.I t
was previously reported that a subset of the human gfpt-1
sequence served as a Tn7 target in vivo when transposition
was performed in E.coli (19). However, this study did not
precisely determine the relative frequency of Tn7 transposi-
tion into the human sequence as compared with the E.coli
sequence. Here, we have shown that TnsD binding, and
hence, the frequency of Tn7 transposition into the human
gfpt-1 sequence is comparable with the glmS-containing tar-
get. We also report that the human gfpt-2 sequence serves as a
target for Tn7 transposition. In contrast, the yeast gfa-1
sequence, which also bears considerable homology to glmS
and the human target analogs, is neither able to bind TnsD nor
target Tn7 transposition by our assays.
Our results show the following trend in the ability of the
eukaryotic analogs to function as target sites for Tn7: glmS ﬃ
gfpt-1 > gfpt-2 >>> gfa-1; and most importantly, Tn7 trans-
position in vitro, or the lack thereof, closely mirrors TnsD
binding to these eukaryotic target sequences.
It has been reported that TnsD binds the human gfpt-1 and
gfpt-2 sequences, and the yeast gfa-1 sequence with signiﬁc-
antly reduced afﬁnity when compared with the glmS sequence
(20). This TnsD-binding study used 20 bp DNA duplexes
containing the sequence from +29 to +48 (see Figure 1),
which does not completely correspond to the TnsD-binding
site (20).
Sequence-specific recognition of target DNA by TnsD
It is intriguing that Tn7 recognizes and makes insertions
adjacent to the human gfpt-1 and gfpt-2 sequences but avoids
the yeast gfa-1 sequence. A comparison of these DNA
sequences (Figure 1) shows that they primarily differ at the
third ‘wobble’ position of multiple codons; certain changes in
the glmS sequence continue to allow TnsD binding, whereas
other alterations completely abolish TnsD binding. Therefore,
TnsD presents aninteresting case of a sequence-speciﬁcDNA-
binding protein that recognizes a highly conserved sequence,
but allows some ﬂexibility within the binding site to incorp-
orate DNA sequence changes due to base wobble. It is very
likely that Tn7 target sites exist within glmS analogs in the
genomes of other organisms ranging from bacteria to the
higher chordates. Indeed, the sequencing of bacterial genomes
has revealed Tn7 and Tn7-like transposons adjacent to the
glmS analogs in multiple cases.
Tn7 is unique among transposons, in that it encodes a
sequence-speciﬁc DNA-binding protein, TnsD, for the site-
speciﬁc recognition of its target DNA. In E.coli, Tn7 trans-
position to locations other than attTn7, termed pseudo-att sites
(bearinghomologytotheglmS sequence),isobservedatavery
low frequency (10000 times less frequent than the glmS target
sequence) (21). The inability of TnsD to bind the analogous
yeastgfa-1sequenceanduseitasatarget forTn7transposition
further attests to the stringent target site selectivity of Tn7, a
characteristic that is highly desirable in a DNA delivery agent
for potential gene therapy applications.
Multiple human targets for site-specific transposition
by Tn7
We have found that Tn7 can transpose in vitro adjacent to the
human gfpt-1 and gfpt-2 sequences, in a site- and orientation-
speciﬁc manner; transposition activity for the gfpt-1 target is at
least comparable with the corresponding bacterial target DNA,
and slightly reduced for the gfpt-2 target. In addition to the
glmS analogs in the human genome, there also exists a target
site on chromosome 11, which is identical to the E.coli attTn7
target sequence. We already know from the sequence that this
Figure 4. Assembly of a nucleosome core particle on the human gfpt-1 target
reduces Tn7 transposition. The left panel shows an EMSA containing: free
target DNA in lane 0, the nucleosome core particle when assembled on the
target DNA in lane 1 and the assembled nucleosome core particle under the
conditionsof the Tn7 transposition reactionin lane 2. The letters F and N mark
lanes containing reactions with either free or nucleosomal DNA, respectively.
Bands corresponding to free and nucleosomal DNA are also marked. The right
panel shows the results of the Tn7 transposition reaction on free and
nucleosome-bound target DNA. Lanes 4 and 5 correspond to TnsABC+D-
mediated transposition into free and nucleosomal DNA. Lanes 3 and 6 are
controls to which none of the Tns proteins was added. Rest as in Figure 2A.
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not associated with any genes, should serve as an efﬁcient
target site for Tn7. Although glmS sequences amongst bacteria
tend to show some variation, the att sequence in the human
clone is identical to the E.coli attTn7 sequence, suggesting that
this att sequence could be the result of contaminating E.coli
sequence. (A BLAST search of the180 bp sequence surround-
ing the att site in the human clone (RP11-159C12) shows that
the entire sequence is identical to sequences found in several
pBAC cloning vectors, which are known to contain the attTn7
target sequence.) Furtherstudies need tobe carriedoutto show
that there is a chromosomal version of the E.coli attTn7,a s
seen in clone RP11-159C12.
These observations imply that Tn7 transposition could
deliver DNA sequences of choice in a site- and orientation-
speciﬁc manner at three locations within the human cell:
adjacent to the sequence identical to attTn7 on chromosome
11, and also adjacent to the gfpt-1 (location 2p13) and the gfpt-
2 (location 5q34–q35) genes.
We have also shown that a nucleosome positioned over the
gfpt-1 target sequence can reduce transposition by likely
occluding the target DNA from the Tns proteins. However,
this observation does not preclude the ability of the human
gfpt-1/2 sequences to serve as a target for Tn7 transposition for
the following reasons: ﬁrst, very little is known about chro-
matin structure around the C-terminus of the gfpt-1 and gfpt-2
genes (8) and the Tn7 target site DNA may not be assembled
intonucleosomesinvivo;andsecond,even ifit were tocontain
nucleosomes, chromatinstructure is dynamic in vivo, when the
putative target site DNA may become at least transiently
accessible to the Tns proteins. Although chromatin structure
may affect the relative Tn7 transposition frequency in vivo,
the presence of three separate targets sites and the dynamic
nature of chromatin structure mean that it does not pose an
insurmountable obstacle to Tn7 transposition in human cells.
We have shown directly target sequences in the human
genome for site- and orientation-speciﬁc Tn7 transposition.
We have also seen that the Tn7 target selector protein,
TnsD, can tolerate limited and very speciﬁc changes in target
sequence. Do the abovementioned observations imply that a
large number of potential target sites will be available for Tn7
transposition in the human genome? While we cannot rule out
the existence of additional target sites, our experience with
Tn7 transposition in bacterial genomes points to a very lim-
ited number of high afﬁnity target sites. For example, The
frequency of Tn7 transposition into attTn7 is very high and
estimated to be  1–10% in E.coli (22) and transposition into
attTn7-like or pseudo-att sites, when attTn7 is unavailable,
occurs at a very low frequency (10000 times less than
attTn7) (21). Moreover, our results with the yeast sequence
here also attest to Tn7’s ability to avoid other attTn7-like
target sites in the genome. Similarly, degenerate att-like target
sequences may be available in the human genome, but the
transposition frequency to these sites will be very signiﬁcantly
reduced and we believe that Tn7 will preferentially transpose
to the three high afﬁnity human target sites on chromosomes 2,
5 and 11 described here. It is, therefore, reasonable to expect
Tn7 to serve as an efﬁcient tool for targeted DNA delivery.
Several other observations bode well for the potential use of
Tn7 as a speciﬁc DNA delivery tool for gene therapy. (i) The
repertoire of Tn7 also includes a mechanism of transposition
immunity, i.e. the presence of a Tn7 element at the target site
prevents further use of the target and multiple insertions are
avoided (1). Thus, one would expect a single copy of Tn7 to be
inserted adjacent to the gfpt-1 or the gfpt-2 genes in an
orientation-speciﬁc manner. (ii) The actual site of Tn7 inser-
tion is located downstream of the gfpt-1/2 genes, and so, it is
very likely that Tn7 insertion will prove to be non-deleterious
to the cell. (iii) There may also be particular advantages in
employing a bacterial transposon for site-speciﬁc delivery in
human cell lines, in that Tn7 may be able to bypass cellular
mechanisms speciﬁcally evolved to restrict eukaryotic mobile
elements. (iv) Finally, bacterial proteins have been success-
fully expressed in human cell lines, including the Cre recom-
binase for the very purpose of gene therapy (23). All of these
factors are encouraging for the potential expression of func-
tional Tns proteins to carry out site-speciﬁc Tn7 transposition
in the human cell.
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